Materias dentro de su búsqueda.
Mostrando 21,521 - 21,534 Resultados de 21,534 Para Buscar '"títere"', tiempo de consulta: 0.31s Limitar resultados
  1. 21521
    “…The effect of cationic ions on phage adsorption was evaluated. The optimal titer of bacteriophage was determined to reduce the concentration of the CRKP strain. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Isolation, characterization, therapeutic potency, and genomic analysis of a novel bacteriophage vB_KshKPC-M against carbapenemase-producing Klebsiella pneumoniae strains (CRKP) isolated from Ventilator-associated pneumoniae (VAP) infection of COVID-19 patients
  2. 21522
    “…Following incubation, cell viability was assessed by ATP quantification using the CellTiter-Glo (Promega) assay. Fresh NE tumors were dissociated and injected into polydimethylsiloxane bioreactors in a matrigel and collagen suspension for 3D culture experiments. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2018 Synaptic vesicle 2 receptors as a novel targets for neuroendocrine cancer therapy
  3. 21523
    “…The median serum IgG antibody titers were 1: 960. Dosing, phase 1. Severe group (n=14): 71% received two CP bags (400 ml) and 29% three CP bags (600 mL). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Phase I and Preliminary Results of a Phase II Study (TERAPLASCoV2) of Convalescent Plasma in Patients with Severe and Life-Threatening Pneumonia Caused By Sars-Cov-2
  4. 21524
    “…As recommended by the manufacturer, titers ≥0.8 U/mL were considered positive, the highest value being >250 U/mL. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Profound B-Cell Lymphopenia Is a Major Factor Predicting Poor Humoral Response after BNT162b2 mRNA Sars-Cov-2 Vaccines in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
  5. 21525
    “…The concentration was determined using an AAV titration kit (Takara). The titer for AAV2-TIPE2 was 4.7 × 10⁁12 GCP/ml. Animals. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Poster 206: TIPE2 Mitigates the Histopathology of Osteoarthritis in An Accelerate Aging Mouse Model
  6. 21526
    “…PK/PD/Immunogenicity • Change in serum ravulizumab concentrations over time • Change in serum free and total C5 concentrations over time • Incidence and titer of anti-ALXN1210 antibodies Biomarkers • Change in absolute level of soluble biomarkers in blood associated with complement activation, inflammatory processes, and hypercoagulable states over time Exploratory • Incidence of progression to renal failure requiring dialysis at Day 29 • Time to clinical improvement (based on a modified 6-point ordinal scale) over 29 days • SF-12 Physical Component Summary (PCS) and Mental Component Summary (MCS) scores at Day 29 (or discharge), Day 60, and Day 90 • EuroQol 5-dimension 5-level (EQ-5D-5L) scores at Day 29 (or discharge), Day 60, and Day 90 TRIAL DESIGN: This is a multicenter Phase 3, open-label, randomized, controlled, study. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial
  7. 21527
    “…The rationale for including donors with severe disease is to maximize the probability of collecting convalescent plasma units with high titer of neutralizing antibodies, as the technology to measure this specific type of antibodies is not routinely available in Peru. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial
  8. 21528
    “…To assess the increase in SARS-CoV-2-specific binding antibody titers in IFN-β compared to control group (day 28). 5. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial
  9. 21529
    “…Those who achieved seroconversion after the third dose (n=10) had significantly higher titers post-dose 2 (median 12, IQR 3.0-40.8) compared to those who remained seronegative (n=14) (median 2.2, IQR 0.5-5.1, p<0.01), although both median values are considered below the threshold by the manufacturer. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Humoral Response to mRNA Vaccines BNT162b2 and mRNA-1273 COVID-19 in Chronic Lymphocytic Leukemia Patients
  10. 21530
    “…. • Viral load, changes in antibody titers and cytokine profiles are analysed in an exploratory manner using paired non-parametric tests (before – after treatment). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial
  11. 21531
    por Akova, Murat, Unal, Serhat
    Publicado 2021
    “…Secondary efficacy endpoints are the incidence of hospitalization/mortality rates among one or two dose regimens, duration of immunogenicity rates up to 120 days, the seroconversion rate, the seropositivity rate, neutralizing antibody titer, and IgG levels 14 days after each dose of vaccination. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial
  12. 21532
    “…Vaccination at least six months after anti-CD20 treatment, likely co-incident with recovery of the B-cell compartment, was associated with positive blocking antibody titers. These data suggest that booster vaccination strategies are more likely to succeed in lymphoma patients who have not received anti-CD20 treatment for at least 6 months and that those patients with recent anti-CD20 treatment may benefit most from passive immunization strategies. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma
  13. 21533
    “…Convalescent plasma (CP), 2 units at screening/baseline visit (day 0) or day 1; CP is defined by the presence of neutralizing anti-SARS-CoV-2 antibodies with titers ≥ 1:160; individuals with body weight ≥ 150 kg will receive a third unit of plasma on day 3. 2. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial
  14. 21534
    por Tan, IB, Chang, Ellen T., Chen, Chien-Jen, Hsu, Wan-Lun, Chien, Yin-Chu, Hildesheim, Allan, McKay, James D., Gaborieau, Valerie, Kaderi, Mohamed Arifin Bin, Purnomosari, Dewajani, Voegele, Catherine, LeCalvez-Kelm, Florence, Byrnes, Graham, Brennan, Paul, Devi, Beena, Li, L., Zhang, Y., Fan, Y., Sun, K., Du, Z., Sun, H., Chan, A. T., Tsao, S. W., Zeng, Y. X., Tao, Q., Busson, Pierre, Lhuillier, Claire, Morales, Olivier, Mrizak, Dhafer, Gelin, Aurore, Kapetanakis, Nikiforos, Delhem, Nadira, Mansouri, Sheila, Cao, Jennifer, Vaidya, Anup, Frappier, Lori, Wai, Lo Kwok, Chen, Sui-Hong, Du, Jin-lin, Ji, Ming-Fang, Huang, Qi-Hong, Liu, Qing, Cao, Su-Mei, Doolan, Denise L., Coghill, Anna, Mulvenna, Jason, Proietti, Carla, Lekieffre, Lea, Bethony, Jeffrey, Hildesheim, and Allan, Fles, Renske, Indrasari, Sagung Rai, Herdini, Camelia, Martini, Santi, Isfandiari, Atoillah, Rhomdoni, Achmad, Adham, Marlinda, Mayangsari, Ika, van Werkhoven, Erik, Wildeman, Maarten, Hariwiyanto, Bambang, Hermani, Bambang, Kentjono, Widodo Ario, Haryana, Sofia Mubarika, Schmidt, Marjanka, Tan, IB, O’Sullivan, Brian, Ozyar, Enis, Lee, Anne W. M., Zeng, Mu-Sheng, Gao, Xiaojiang, Tang, Minzhong, Martin, Pat, Zeng, Yi, Carrington, Mary, Coghill, Anna E., Bu, Wei, Nguyen, Hanh, Hsu, Wan-Lun, Yu, Kelly J., Lou, Pei-Jen, Wang, Cheng-Ping, Chen, Chien-Jen, Hildesheim, Allan, Cohen, Jeffrey I., King, Ann D., Chien, Yin-Chu, Hsu, Wan-Lun, Yu, Kelly J., Chen, Tseng-Cheng, Lin, Ching-Yuan, Tsou, Yung-An, Leu, Yi-Shing, Laio, Li-Jen, Chang, Yen-Liang, Wang, Cheng-Ping, Hua, Chun-Hun, Wu, Ming-Shiang, Hsiao, Chu-Hsing Kate, Lee, Jehn-Chuan, Tsai, Ming-Hsui, Cheng, Skye Hung-Chun, Lou, Pei-Jen, Hildesheim, Allan, Chen, Chien-Jen, Hsu, Wan-Lun, Yu, Kelly J., Chien, Yin-Chu, Chen, Tseng-Cheng, Lin, Ching-Yuan, Tsou, Yung-An, Leu, Yi-Shing, Liao, Li-Jen, Chang, Yen-Liang, Yang, Tsung-Lin, Hua, Chun-Hun, Wu, Ming-Shiang, Hsiao, Chu-Hsing Kate, Lee, Jehn-Chuan, Tsai, Ming-Hsui, Cheng, Skye Hung-Chun, Ko, Jenq-Yuh, Hildesheim, Allan, Chen, Chien-Jen, Ko, Josephine Mun Yee, Dai, Wei, Kwong, Dora, Ng, Wai Tong, Lee, Anne, Ngan, Roger Kai Cheong, Yau, Chun Chung, Tung, Stewart, Lung, Maria Li, Ji, Mingfang, Sheng, Wei, Ng, Mun Hon, Cheng, Weimin, Yu, Xia, Wu, Biaohua, Wei, Kuangrong, Zhan, Jun, Zeng, Yi Xin, Cao, Su Mei, Xia, Ningshao, Yuan, Yong, Cui, Qian, Xu, Miao, Bei, Jin-Xin, Zeng, Yi-Xin, Şahin, B, Dizman, A, Esassolak, M, İkizler, A Saran, Yıldırım, HC, Çaloğlu, M, Atalar, B, Akman, F, Demiroz, C, Atasoy, BM, Canyilmaz, E, Igdem, S, Ugurluer, G, Kütük, T, Akmansoy, M, Ozyar, E, Sommat, Kiattisa, Wang, Fu Qiang, Kwok, Li-Lian, Tan, Terence, Fong, Kam Weng, Soong, Yoke Lim, Cheah, Shie Lee, Wee, Joseph, Casanova, M, Özyar, E, Patte, C, Orbach, D, Ferrari, A, Cristine, VF, Errihani, H, Pan, J, Zhang, L, Liji, S, Grzegorzewski, K, Gore, L, Varan, A, Hutajulu, Susanna Hilda, Khuzairi, Guntara, Herdini, Camelia, Kusumo, Henry, Hardianti, Mardiah Suci, Taroeno-Hariadi, Kartika Widayati, Purwanto, Ibnu, Kurnianda, Johan, Messick, Troy E., Malecka, Kimberly, Tolvinski, Lois, Soldan, Samantha, Deakyne, Julianna, Song, Hui, van den Heuvel, Antonio, Gu, Baiwei, Cassel, Joel, McDonnell, Mark, Smith, Garry R., Velvadapu, Venkata, Bian, Haiyan, Zhang, Yan, Carlsen, Marianne, Chen, Shuai, Donald, Alastair, Lemmen, Christian, Reitz, Allen B., Lieberman, Paul M., Chan, King Chi, Chan, Lai Sheung, Lo, Kwok Wai, Yip, Timothy Tak Chun, Ngan, Roger Kai Cheong, Kahn, Michael, Lung, Maria Li, Mak, Nai Ki, Liu, Fei-Fei, Khaali, Wafa, Thariat, Juliette, Fantin, Laurence, Spirito, Flavia, Khyatti, Meriem, Driss, El Khalil Ben, Olivero, Sylvain, Maryanski, Janet, Doglio, Alain, Xia, Mengxue, Xia, Yunfei, Chang, Hui, Shaw, Rachel, Rahaju, Pudji, Hardianti, Mardiah Suci, Wisesa, Sindhu, Taroeno-Harijadi, Kartika Widayati, Purwanto, Ibnu, Hariwiyanto, Bambang, Dhamiyati, Wigati, Kurnianda, Johan, Tan, Sang-Nee, Sim, Sai-Peng, Yusuf, Muhtarum, Romdhoni, Ahmad C., K, Widodo Ario, Rantam, Fedik Abdul, Sugiyanto, Aryati, Lina, Adi-Kusumo, Fajar, Hardianti, Mardiah Suci, Bintoro, SY, Oktriani, R., Herawati, C., Surono, A., Haryana, Sofia M., Zhong, L., Li, L., Ma, B. B., Chan, A. T., Tao, Q., Kalra, M., Ngo, M., Perna, S., Leen, A., Lapteva, N., Rooney, C. M., Gottschalk, S., Mustikaningtyas, Elida, Herawati, Sri, Romdhoni, Achmad C., Ji, Mingfang, Xu, Yarui, Cheng, Weimin, Ge, Shengxiang, Li, Fugui, Ng, M. H., Tan, Louise SY, Wong, Benjamin, Lim, C. M., Romdhoni, Achmad C., Rantam, Fedik A., Kentjono, Widodo Ario, Madani, Deasy Z., Akbar, Nur, Permana, Agung Dinasti, Herdini, Camelia, Indrasari, Sagung Rai, Fachiroh, Jajah, Hartati, Dwi, Rahayudjati, T. Baning, Darwis, Iswandi, Hutajulu, Susanna Hilda, Hariwiyanto, Bambang, Dhamiyati, Wigati, Purwanto, Ibnu, Taroeno-Hariadi, Kartika Widayati, Kurnianda, Johan, Wisesa, Sindhu, Hardianti, Mardiah Suci, Hutajulu, Susanna Hilda, Taroeno-Harijadi, Kartika Widayati, Purwanto, Ibnu, Herdini, Camelia, Dhamiyati, Wigati, Kurnianda, Johan, Anwar, Khoirul, Hutajulu, Susanna Hilda, Indrasari, Sagung Rai, Dwidanarti, Sri Retna, Purwanto, Ibnu, Taroeno-Hariadi, Kartika Widayati, Kurnianda, Johan, Pramana, Dominicus Wendhy, Hutajulu, Susanna Hilda, Hariwiyanto, Bambang, Dhamiyati, Wigati, Purwanto, Ibnu, Taroeno-Hariadi, Kartika Widayati, Kurnianda, Johan, Safitri, Diah Ari, Hutajulu, Susanna Hilda, Herdini, Camelia, Danarti, Sri Retna Dwi, Purwanto, Ibnu, Taroeno-Hariadi, Kartika Widayati, Kurnianda, Johan, Taroeno, Suryo A, Wisesa, Sindhu, Taroeno-Hariadi, Kartika Widayati, Purwanto, Ibnu, Hariwiyanto, Bambang, Dhamiyati, Wigati, Kurnianda, Johan, Wijaya, I., Oehadian, A., Prasetya, D., Hsu, Wan-Lun, Chien, Yin-Chu, Yu, Kelly J, Wang, Cheng-Ping, Lin, Ching-Yuan, Tsou, Yung-An, Leu, Yi-Shing, Liao, Li-Jen, Chang, Yen-Liang, Ko, Jenq-Yuh, Hua, Chun-Hun, Wu, Ming-Shiang, Hsiao, Chu-Hsing Kate, Lee, Jehn-Chuan, Tsai, Ming-Hsui, Cheng, Skye Hung-Chun, Lou, Pei-Jen, Hildesheim, Allan, Chen, Chien-Jen, Rahman, Sukri, Budiman, Bestari J., Novialdi, Rahmadona, Lestari, Dewi Yuri, Yin, C., Foussadier, A., Blein, E., Chen, C., Ammour, N. Bournet, Khiatti, M., Cao, S., Marzaini, Dewi Syafriyetti Soeis, Hartati, Dwi, Rahayujati, Baning, Herdini, Camelia, Fachiroh, Jajah, Gunawan, L., Mubarika Haryana, S., Surono, A., Herawati, C., Hartono, Michael, Fachiroh, Jajah, Intansari, Umi, Paramita, Dewi Kartikawati, Akbar, Akmal, Fachiroh, Jajah, Paramita, Dewi Kartikawati, Hermawan, Benny, Rahayudjati, T. Baning, Paramita, Dewi K., Fachiroh, Jajah, Argy, Gabriella, Fachiroh, Jajah, Paramita, Dewi Kartikawati, Hutajulu, Susanna Hilda, Sihotang, Theodora Caroline, Fachiroh, Jajah, Intansari, Umi, Paramita, Dewi Kartikawati, Wahyono, Daniel Joko, Soeharso, Purnomo, Suryandari, Dwi Anita, Lisnawati, Musa, Zanil, Hermani, Bambang, Daker, Maelinda, Tzen, Yeo Jiun, Bakar, Norhasimah, Rahman, Asma’ Saiyidatina Aishah Abdul, Ahmad, Munirah, Chia, Yeo Tiong, Beng, Alan Khoo Soo, Sasikirana, Widyandani, Wardana, Tirta, Radifar, Muhammad, Herawati, Cita, Surono, Agus, Haryana, Sofia Mubarika
    Publicado 2016
    “…Herawati P16 IgA response to native early antigen (IgA-EAext) of Epstein-Barr virus (EBV) in healthy population and nasopharyngeal carcinoma (NPC) patients: the potential for diagnosis and screening tools Michael Hartono, Jajah Fachiroh, Umi Intansari, Dewi Kartikawati Paramita P17 IgA responses against Epstein-Barr Virus Early Antigen (EBV-EA) peptides as potential candidates of nasopharyngeal carcinoma detection marker Akmal Akbar, Jajah Fachiroh, Dewi Kartikawati Paramita P18 Association between smoking habit and IgA-EBV titer among healthy individuals in Yogyakarta, Indonesia Benny Hermawan, T Baning Rahayudjati, Dewi K Paramita, Jajah Fachiroh P19 Epstein-Barr virus IgA titer comparison of healthy non-family individuals and healthy first degree family of NPV patients Gabriella Argy, Jajah Fachiroh, Dewi Kartikawati Paramita, Susanna Hilda Hutajulu P20 Identification of EBV Early Antigen (EA) derived peptides for NPC diagnosis Theodora Caroline Sihotang, Jajah Fachiroh, Umi Intansari, Dewi Kartikawati Paramita P21 Host-pathogen study: relative expression of mRNA BRLF1 Epstein-Barr virus as a potential biomarker for tumor progressivity and polymorphisms of TCRBC and TCRGC2 host genes related to genetic susceptibility on nasopharyngeal carcinoma Daniel Joko Wahyono, Purnomo Soeharso, Dwi Anita Suryandari, Lisnawati, Zanil Musa, Bambang Hermani P22 In vitro efficacy of silvestrol and episilvestrol, isolated from Borneo, on nasopharyngeal carcinoma, a major cancer in Borneo Maelinda Daker, Yeo Jiun Tzen, Norhasimah Bakar, Asma’ Saiyidatina Aishah Abdul Rahman, Munirah Ahmad, Yeo Tiong Chia, Alan Khoo Soo Beng P23 The expression of mir-141 in patients with nasopharyngeal cancer Widyandani Sasikirana, Tirta Wardana, Muhammad Radifar, Cita Herawati, Agus Surono, Sofia Mubarika Haryana…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Proceedings of the 7th Biannual International Symposium on Nasopharyngeal Carcinoma 2015: Yogyakarta, Indonesia. 4-6 June 2015
Herramientas de búsqueda: RSS